TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial the Use of Levonorgestrel-releasing Intrauterine System Versus Etonogestrel Implant in Endometriosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women aged 18 to 45~* Absence of pregnancy~* Patients with chronic pelvic pain and / or dysmenorrhea with pain scores ≥ 4 on EVA pain and surgical and histopathological diagnosis of endometriosis in 14 last three months to two years, according to the current classification of the American Society for Reproductive Medicine and Enzian classification.~* Accept participate and sign the consent form and clarified~Exclusion criteria:~* Current wish to get pregnant~* I just want to use the LNG-IUS as treatment~* Contraindication to the use of LNG-IUS: Current pelvic inflammatory disease or appellant; infection of the lower genital tract; infected abortion during the last 3 months; purulent cervicitis; uterine or cervical malignancy; bleeding abnormal uterine undiagnosed; congenital uterine anomalies or acquired conditions associated with increased susceptibility to infections; acute liver disease or liver tumors; hypersensitivity to LNG.~* Contraindications to the use of ENG implants: pregnancy or suspected pregnancy;~* Active venous thromboembolic disorder; presence or history of liver disease serious as liver function values have not returned to normal; progestogen dependent tumors; abnormal bleeding undiagnosed; hypersensitivity to any component of implante.~* Abusive use of alcohol and / or other illicit drugs.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- levonorgestrel & etonogestrel (Type: EXPERIMENTAL): Levonorgestrel releasing intrauterine system~Other names:~Mirena.
- etonogestrel (Type: ACTIVE_COMPARATOR): Etonogestrel implant:~Other name: Implanon Releasing 20μg/day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose-finding Study for the Ultralow-dose Levonorgestrel Intrauterine Contraceptive System (LCS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Women with or without children and good general health and in need of contraception.~* Regular menstrual cycle without hormonal contraceptives.~Exclusion Criteria:~* Pregnant or lactating.~* Last delivery or abortion less than 12 weeks ago.~* Previous pregnancies outside the womb.~* Previous pelvic infections.~* Abnormal bleeding.~* Abnormal uterine cavity.~* Climacteric signs.~* Genital cancer.~* Liver diseases.~* Alcoholism or drug abuse.

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- LCS12 (Type: EXPERIMENTAL): Levonorgestrel intrauterine contraceptive system (LCS) releasing 12 microg/24h in vitro
- LCS16 (Type: EXPERIMENTAL): Levonorgestrel intrauterine contraceptive system (LCS) releasing 16 microg/24h in vitro
- IUS20 (Mirena) (Type: ACTIVE_COMPARATOR): Levonorgestrel intrauterine system (IUS) releasing 20 microg/24h in vitro

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Organic Diet Intervention in Primary School Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy children aged 10-12 years, residing in Cyprus over the last five years who consume primarily (\> 80%) conventional food (non-organic).~Exclusion Criteria:~* Children with chronic conditions (e.g. diabetes, asthma) or allergies in food (e.g. gluten, lactose tolerance)

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 12 Years
- Healthy Volunteers: t

Study Arms:
- Conventional phase (Type: NO_INTERVENTION): During the conventional phase, participants are asked to maintain their usual dietary choices for 40 days.
- Organic phase (Type: EXPERIMENTAL): During the organic phase, participants are asked to follow strictly the two 20-day organic dietary menus provided to them for 40 days. The organic dietary menus were prepared by a certified dietitian. The meals of the organic phase are prepared by a certified organic restaurant and are delivered to school every day except Sunday. For the meals of breakfast and afternoon snacks, children choose their preferred options for the week on the Friday of the previous week according to a list of organic food items and the products for these meals are delivered on Saturday along with the rest meals. Parents are responsible to pick-up the organic meals from school and ensure that the participating children have access to them.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female Japanese participants ≥20 years of age~* Diagnosis of chronic kidney disease (CKD) based on an estimated glomerular filtration rate ≤60 milliliters per minute per 1.73 meters squared (mL/min/1.73 m\^2)~* Hemoglobin (Hb) ≤10.5 grams per deciliter (g/dL)~* Not currently being treated with dialysis and not expected to start dialysis within 3 months of screening~Exclusion Criteria:~* Anemia due to a cause other than CKD or presence of active bleeding or recent blood loss~* Sickle cell disease, myelodysplastic syndromes, bone marrow fibrosis, hematologic malignancy, myeloma, hemolytic anemia, thalassemia, or pure red cell aplasia~* Red blood cell transfusion within 4 weeks prior to or during screening~* Intravenous iron within 4 weeks prior to or during screening~* Any use of erythropoiesis-stimulating agents within 6 weeks prior to or during screening

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vadadustat, Dose 1 (Type: EXPERIMENTAL): Daily oral dose
- Vadadustat, Dose 2 (Type: EXPERIMENTAL): Daily oral dose
- Vadadustat, Dose 3 (Type: EXPERIMENTAL): Daily oral dose
- Placebo (Type: PLACEBO_COMPARATOR): Daily oral dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* For subjects who participated in F13CD-1725:~* Previous participation (means up to and inclusive Visit 16, (End of Trial)) in F13CD-1725~* For all other subjects:~* Diagnosis of congenital FXIII A-subunit deficiency (confirmed by genotyping at screening visit or documented results from previously performed genotyping)~* Body weight at least 20 kg~Exclusion Criteria:~* Known neutralizing antibodies (inhibitors) towards FXIII~* Any known congenital or acquired coagulation disorder other than congenital FXIII deficiency~* Platelet count (thrombocytes) of less than 50 × 109/L. For subjects who participated in F13CD-1725 platelet count from visit 15 in F13CD-1725 must be used for evaluation.~* Females of childbearing potential who are pregnant, breastfeeding or are not using adequate contraceptive methods

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and PK Study of Single Doses of ABT-450 With and Without Ritonavir to Treat Hepatitis C Virus (HCV) Genotype 1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* overall healthy subjects~* non-childbearing potential females included~Exclusion Criteria:~* history of significant sensitivity to any drug~* positive test for HAV IgM, HBsAg, anti-HCV Ab or anti-HIV Ab~* history of gastrointestinal issues or procedures~* history of seizures, diabetes or cancer (except basal cell carcinoma)~* clinically significant cardiovascular, respiratory (except mild asthma), renal, gastrointestinal, hematologic, neurologic, thyroid, or any uncontrolled medical illness or psychiatric disorder~* use of tobacco or nicotine-containing products with the 6-month period prior to study drug administration~* donation or loss of 550 mL or more blood volume or receipt of a transfusion of any blood product within 8 weeks prior to study drug administration~* abnormal screening laboratory results that are considered clinically significant by the investigator~* current enrollment in another clinical study~* previous enrollment in this study~* recent (6-month) history of drug/alcohol abuse that could preclude adherence to the protocol~* pregnant or breastfeeding female~* requirement for any OTC and/or prescription medication, vitamins and/or herbal supplements on a regular basis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): ABT-450
- 2 (Type: PLACEBO_COMPARATOR): Placebo for ABT-450
- 3 (Type: ACTIVE_COMPARATOR): ABT-450/ritonavir
- 4 (Type: PLACEBO_COMPARATOR): Placebo for ABT-450/placebo for ritonavir

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Triple Combination Therapy Study of Boceprevir, Pegasys and Copegus in Previously Untreated Patients With Genotype 1 Chronic Hepatitis C

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients \>/=18 years of age~* Chronic liver disease consistent with chronic hepatitis C, genotype 1 infection~* Serum HCV RNA quantifiable at screening~* Patients who have not been previously treated with pegylated interferon (IFN), standard IFN, RBV or any direct acting anti-viral agent~* Compensated liver disease (Child-Pugh Grade A clinical classification for patients with cirrhosis: total score \</=6)~* Negative urine or blood pregnancy test (for women of childbearing potential)~Exclusion Criteria:~* Women with ongoing pregnancy or breast feeding~* Male partners of women who are pregnant~* Therapy with any systemic anti-viral, anti-neoplastic or immunomodulatory treatment \</=6 months prior to the first dose of study drug~* Any investigational drug \</=6 weeks prior to the first dose of study drug~* History or other evidence of decompensated liver disease~* History or other evidence of a medical condition associated with chronic liver disease other than chronic hepatitis C~* Signs or symptoms of hepatocellular carcinoma~* Co-infection with HCV genotypes other than genotype 1~* Co-infection with hepatitis A, hepatitis B, and/or human immunodeficiency virus (HIV)~* Any patient with an increased risk for anemia~* History of severe psychiatric disease~* History of immunologically mediated, chronic pulmonary, or severe cardiac disease~* Current diseases that are not adequately controlled

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dual Combination Therapy (Type: EXPERIMENTAL): None
- Triple Combination Therapy (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ASpirin vs Triflusal for Event Reduction In Atherothrombosis Secondary Prevention (ASTERIAS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a stable coronary artery disease (CAD)~* Patients with a history of non-cardioembolic ischemic stroke.~Exclusion Criteria:~* Hypersensitivity reaction or contraindication to triflusal or aspirin~* Active bleeding or history of severe bleeding (peptic ulcer, trauma or intracranial hemorrhage)~* Blood coagulation disorders~* Uncontrolled severe hypertension~* Pregnancy or breastfeeding~* Liver disease (alanine or aspartate aminotransferase more than 3 times the upper normal limit)~* Malignancy that may potentially increase the risk of hemorrhage~* Drug or alcohol abuse~* HIV infection~* Chronic disorders requiring long-term treatment with systemic nonsteroidal anti-inflammatory drugs (NSAIDs).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aspirin (Type: ACTIVE_COMPARATOR): 100mg/day
- Triflusal (Type: ACTIVE_COMPARATOR): 300mg twice or 600mg once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intranasal Lorazepam Versus Intramuscular Paraldehyde in Paediatric Convulsions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Children aged between 2 months and 12 years~* Presenting with generalised convulsions~Exclusion Criteria:~* Any child who had received an anticonvulsant agent within 1 hour of presentation~* Seizure stopped with rapid cooling or treatment of hypoglycaemia~* Features consistent with organophosphate poisoning, hepatic or hypertensive encephalopathy

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 12 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pulmonary Arterial Denervation in Patients With Pulmonary Hypertension Associated With the Left Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age\>18yr~* ReactivePulmonary Hypertension in Left Heart Failure: mPAP≥25 mmHg, PCWP\>15 mmHg and pulmonary vascular resistance (PVR) \[The PVR =(mPAP-PCWP)/ carbon monoxide\]\>3.0 woods unit~* Voluntary acceptance of all follow-up assessment of program requirements.~Exclusion Criteria:~* WHO group I, III, IV, V pulmonary artery hypertension~* Severe Renal dysfunction (Ccr\<30 ml/min)~* Blood platelet count\<100,000/L~* Expected life span\<12-month~* In pregnancy~* Systematical inflammation~* Malignant cancer(s)~* Tricuspid valve stenosis, Supra-pulmonary valve stenosis~* Allergic to studied drugs or metal materials

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pulmonary Arterial Denervation (PADN) (Type: EXPERIMENTAL): Contrast pulmonary artery （PA) angiography was performed to localize the pulmonary artery bifurcation level and calculate the PA diameter.Once the anatomy was deemed acceptable, the radiofrequency ablation catheter was introduced into ostium of the left PA, ostium of the right PA , and the distal bifurcation area of the main PA.This was then maneuvered within the PA to allow energy delivery in a circumferential manner to ensure that the electrodes were tightly in contact with the endovascular surface. About four to eight ablations at 10 W for 60 seconds each were performed in ostium of the left PA, ostium of the right PA , and the distal bifurcation area of the main PA.
- Standard treatment (Type: ACTIVE_COMPARATOR): Patients in the standard treatment group will take their baseline anti-heart failure medications at the original doses, without any changes except when medically required.The anti-heart failure drugs treatment is consistent in both arms.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects with a diagnosis per International League of Associations for Rheumatology (ILAR) criteria of extended oligoarticular juvenile idiopathic arthritis (JIA) between the ages of 2 and 17 years; enthesitis-related arthritis (ERA) between the ages of 12 and 17 years; or psoriatic arthritis (PsA) between the ages of 12 and 17 years.~* \>= 2 active joints and the following for the relevant JIA subtype: extended oligoarticular JIA or PsA with a history of intolerance or an unsatisfactory response to a disease modifying antirheumatic drug (DMARD); or ERA with a history of intolerance or an unsatisfactory response to a nonsteroidal anti-inflammatory drug (NSAID) or a DMARD.~Exclusion Criteria:~* Systemic JIA, persistent oligoarticular JIA, polyarticular JIA, or undifferentiated arthritis per ILAR criteria.~* Other rheumatic diseases.~* Active uveitis within 6 months of the baseline visit.~* Any other significant health problem.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Etanercept 0.8 mg/kg QW up to a maximum dose of 50 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Pancreatic Cancer With Abraxane

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Metastatic pancreatic carcinoma~2. Age \> 18 years~3. Signed Informed Consent~4. Normal hepatic, renal and Bone Marrow functions~Exclusion Criteria:~1. Pregnant and lactating females 2. Previous treatment for metastatic pancreatic disease 3. Known hypersensitivity to nab-paclitaxel 4. Neutrophils \< 1,5 x 10\^9/L~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Abraxane + Gemcitabine (Type: None): Abraxane 125mg by intravenous( IV) infusion + Gemcitabine 1000mg by intravenous on Days 1, 8, 15 of every 21 day cycle until progression

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability Study of MEDI0382 in Japanese Preobese or Obese Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Individuals whose HbA1c range of 7.0% to 10.5% (inclusive) at screening.~* Individuals who are diagnosed with T2DM~* Individuals whose current condition at enrolment (Visit 1) is drug naïve~* BMI within the range of 24 - 40 kg/m2 (inclusive) at screening~Exclusion Criteria:~* Subjects with any of the following results at screening:~* Aspartate transaminase (AST) ≥ 2.5 × upper limit of normal (ULN)~* Alanine transaminase (ALT) ≥ 2.5 × ULN~* Total bilirubin (TBL) ≥ 2 × ULN~* Impaired renal function defined as estimated glomerular filtration rate (eGFR) ≤ 60 mL/minute/1.73 m2 at screening~* Participation in another clinical study with an investigational product administered in the last 30 days or 5 half-lives of the drug (whichever is longer) at the time of screening

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): Placebo per day,SC injection on 48 days.
- MEDI0382 100μg (Type: EXPERIMENTAL): 50 μg/day,SC injection on the first 5 days and 100 μg/day,SC injection on 43 days
- MEDI0382 200μg (Type: EXPERIMENTAL): 50 μg/day,SC injection on the first 5 days, 100 μg/day,SC injection on 7 days and 200 μg/day,SC injection on 36 days.
- MEDI0382 300μg (Type: EXPERIMENTAL): 50 μg/day,SC injection on the first 5 days, 100 μg/day,SC injection on 7 days, 200 μg/day,SC injection on 7 days and 300 μg/day,SC injection on 29 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete